Kikuchi, Taku



School of Medicine, Department of Internal Medicine (Hematology) (Shinanomachi)



Career 【 Display / hide

  • 2010.04

    慶應義塾大学医学部, 血液内科, 助教

Academic Background 【 Display / hide

  • 2005.03

    横浜市立大学, 医学部, 医学科

    日本, Graduated

Licenses and Qualifications 【 Display / hide

  • 医師免許, 2005.04

  • 血液内科専門医, 2012.04

  • 血液指導医, 2014.04

  • 造血細胞移植認定医, 2015.10


Papers 【 Display / hide

  • Successful Treatment of TAFRO Syndrome with Tocilizumab, Prednisone, and Cyclophosphamide

    Kikuchi, T., Shimizu, T., Toyama, T., Abe, R. and Okamoto, S.

    Intern Med  2017.08

    ISSN  0918-2918

     View Summary

    TAFRO syndrome is a rare systemic inflammatory disease characterized by thrombocytopenia, pleural effusion, fever, renal dysfunction, reticulin fibrosis of the bone marrow, and organomegaly. The clinical course varies significantly among patients. However, the prognosis is usually dismal in patients with severe TAFRO syndrome, and no optimal treatment has yet been established. We herein describe the first case of TAFRO syndrome, which was successfully treated with combination therapy consisting of tocilizumab, prednisone, and cyclophosphamide.

  • Successful treatment with bendamustine and rituximab for paraneoplastic pemphigus

    Kikuchi, T., Mori, T., Shimizu, T., Koda, Y., Abe, R., Kurihara, Y., Funakoshi, T., Yamagami, J., Sato, H., Tsunoda, K., Amagai, M. and Okamoto, S.

    Ann Hematol 96 ( 7 ) 1221 - 1222 2017.07

    ISSN  0939-5555

  • Effects of calcineurin inhibitors on sodium excretion in recipients of allogeneic hematopoietic stem cell transplantation

    Saburi, M., Kohashi, S., Kato, J., Koda, Y., Sakurai, M., Toyama, T., Kikuchi, T., Karigane, D., Yuda, S., Yamane, Y., Hashida, R., Abe, R., Nakazato, T., Hirahashi, J., Ogata, M., Okamoto, S. and Mori, T.

    Int J Hematol  2017.05

    ISSN  0925-5710

     View Summary

    Calcineurin inhibitors (CIs) such as cyclosporine A (CSA) and tacrolimus often cause renal dysfunction, resulting in increased serum creatinine, hyperkalemia, and hyperuricemia. However, the effects of CIs on sodium excretion have not been fully elucidated. We retrospectively evaluated the effects of CI administration on sodium excretion in recipients of allogeneic hematopoietic stem cell transplantation (HSCT). Fifty consecutive recipients each of allogeneic HSCT receiving either CSA or tacrolimus (100 patients in total) with available data for weekly fractional excretion of sodium (FENa) for a 4-week period after transplantation were enrolled in this retrospective analysis. No significant differences in patient characteristics were observed between CSA and tacrolimus groups except for the type of donor. FENa was significantly higher at the 3rd (1.25 +/- 0.80) and 4th weeks (1.53 +/- 1.06) after transplantation as compared with that at the 1st week (0.93 +/- 0.51; P < 0.01, P < 0.001, respectively) in the tacrolimus group, but not at any time point in the CSA group. In addition, FENa was significantly higher in the tacrolimus group than the CSA group at the 4th week (1.53 +/- 1.06 vs. 1.13 +/- 0.80; P < 0.05). These results suggest that tacrolimus increases sodium excretion after allogeneic HSCT, and that this effect is minimal with CSA.

  • Hyponatremia associated with human herpesvirus-6 (HHV-6) encephalitis after allogeneic hematopoietic stem cell transplantation: A presentation different from HHV-6 myelitis

    Murakami, K., Kohashi, S., Sakurai, M., Kato, J., Toyama, T., Koda, Y., Yamane, Y., Hashida, R., Abe, R., Yamazaki, R., Kikuchi, T., Shimizu, T., Suzuki, S., Hasegawa, N., Okamoto, S. and Mori, T.

    Int J Hematol  2017.05

    ISSN  0925-5710

     View Summary

    Human herpesvirus-6 (HHV-6) encephalitis and myelitis following allogeneic hematopoietic stem cell transplantation (HSCT) is frequently life-threatening. We retrospectively evaluated the clinical significance of hyponatremia in cases of HHV-6 encephalitis/myelitis. Using an institutional database and medical records, we identified and retrospectively analyzed 16 cases of HHV-6 encephalitis and/or myelitis after allogeneic HSCT. HHV-6 encephalitis and myelitis were defined as the symptoms/signs with HHV-6-DNA in the cerebrospinal fluid. Seizure and memory disorder were defined as symptoms/signs of encephalitis, and dysesthesia and vesicorectal disorder as those of myelitis. Five patients developed encephalitis with or without myelitis, and 11 patients developed myelitis alone. Hyponatremia (median 129.1 mEq/L; range 125.9-130.1) was observed in all five patients with HHV-6 encephalitis at diagnosis, and values were significantly lower than those in patients with HHV-6 myelitis alone (median 137.6; range 134.0-142.2; P < 0.01). In three of the five patients with encephalitis, the decrease in sodium level preceded the clinical onset of encephalitis by one or two days. These results suggest that hyponatremia may be an important manifestation of HHV-6 encephalitis, but not of myelitis, and could be a useful tool for the early prediction or diagnosis of HHV-6 encephalitis.

  • Single-institutional retrospective analysis of Japanese patients with chronic lymphocytic leukemia

    Hashida, R., Kohashi, S., Kato, J., Kikuchi, T., Sakurai, M., Toyama, T., Koda, Y., Yamane, Y., Abe, R., Shimizu, T., Yamazaki, R., Mitsuhashi, T., Murata, M., Okamoto, S. and Mori, T.

    Rinsho Ketsueki 58 ( 4 ) 282 - 286 2017

    ISSN  0485-1439

     View Summary

    Unlike in Western countries, chronic lymphocytic leukemia (CLL) is a rare lymphoid malignancy in Japan, and its clinical features remain to be elucidated in the Japanese population. Therefore, we retrospectively analyzed 29 Japanese CLL patients newly diagnosed at our institute. Seventeen (59%) were male, and their median age was 62 years. With a median follow-up period from diagnosis of 69 months (range, 3-170 months), 9 patients received some form of treatment for CLL. Three patients died of disease progression with or without infection (n=2) or skin cancer (n=1). Five-year overall and treatment-free survival rates were 83% (95%CI, 46-96%) and 67% (95%CI, 45-81%), respectively. Two patients received allogeneic hematopoietic stem cell transplantation for refractory disease, and both were alive without disease relapse at 53 and 110 months, respectively, after transplantation. These results suggest the clinical courses of Japanese patients with CLL to be comparable to those in Western countries. However, future studies of larger numbers of patients are needed to further elucidate the features and long-term clinical courses of CLL in the Japanese population.

display all >>